M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Pharmaceutical Business ReviewThese conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation.Immunology & InflammationRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) Pharmaceutical Business Review These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Immunology & Inflammation Read full story Post navigation Previous: Replimune rebounds to win FDA approval of melanoma drugNext: Intellia finds genetic suspect for liver safety signals with ATTR gene therapy Related Stories M&A / Deals China’s Haisco forms immunology biotech with up to $1.5B from American VCs pharminent August 25, 2026 M&A / Deals Roche commits to lean-mass preservation with Hanmi obesity deal pharminent August 24, 2026 M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026
